<DOC>
	<DOCNO>NCT00831012</DOCNO>
	<brief_summary>Dengue fever , cause dengue virus , major health problem tropical subtropical region world . The purpose study test safety immune response new dengue virus vaccine healthy adult .</brief_summary>
	<brief_title>Safety Immune Response Dengue Virus Vaccine ( rDEN3delta30/31‐7164 ) Healthy Adults</brief_title>
	<detailed_description>More 2 billion people live tropical subtropical region world risk dengue virus infection . Dengue viruses cause dengue fever , well severe dengue hemorrhagic fever/shock syndrome , dengue virus infection lead cause hospitalization death child several tropical Asian country . This study evaluate safety immunogenicity live , attenuate dengue virus call rDEN3delta30/31‐7164 . This study consist two group , Group 1 enrol first . Group 1 participant randomly assign receive either 10^3 PFU rDEN3delta30/31-7164 placebo subcutaneously deltoid . Participants monitor clinic 30 minute receive immunization monitor adverse effect . After , participant ask return clinic approximately every day next 16 day , Day 21 , 28 , 42 , 180 . At visit participant physical clinical exam , vital sign , measure , blood drawn , ask adverse event may experience . Female participant give pregnancy test . In addition , participant ask measure temperature 3 time day record temperature diary first 16 day immunization . If less 90 % participant Group 1 seroconvert DEN3 Group 2A enrol . Group 2A follow procedure Group 1 , receive 10^5 PFU dose rDEN3delta30/31-7164 . If 90 % participant Group 1 seroconvert DEN3 Group 2B enrol . Group 2A follow procedure Group 1 , receive 10^1 PFU dose rDEN3delta30/31-7164 .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult male nonpregnant female 18 50 year age , inclusive . Good general health determine physical exam , laboratory screening , review medical history Available duration study , approximately 26 week post‐vaccination Willing use effective mean contraception duration trial Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease history , physical examination , and/or laboratory study Behavioral , cognitive , psychiatric disease opinion investigator affect ability volunteer understand cooperate requirement study protocol Grade 1 value absolute neutrophil count ( ANC ) , alanine aminotransferase ( ALT ) , serum creatinine , protocol define Any condition opinion investigator would jeopardize safety right volunteer participate n trial would render volunteer unable comply protocol Any significant alcohol drug abuse past 12 month cause medical , occupational , family problem , indicate volunteer history History severe allergic reaction anaphylaxis Severe asthma ( emergency room visit hospitalization within last 6 month ) Positive HIV‐1 serology screen confirmatory assay Positive hepatitis C virus ( HCV ) screen confirmatory assay Positive hepatitis B virus ( HBV ) hepatitis B surface antigen ( HBsAg ) screen Any known immunodeficiency syndrome Use corticosteroid ( exclude topical nasal ) immunosuppressive drug within 30 day prior Study Day 0 Receipt live vaccine within 4 week kill vaccine within 2 week prior Study Day 0 anticipate receipt vaccine 42 day follow Study Day 0 History surgical splenectomy Receipt blood product within past 6 month , include transfusion immunoglobulin anticipate receipt blood product immunoglobulin 42 day follow Study Day 0 History serologic evidence previous dengue virus infection flavivirus infection ( e.g. , yellow fever virus , St. Louis encephalitis , West Nile virus ) Previous receipt yellow fever dengue vaccine ( licensed experimental ) Receipt investigational agent 30 day prior Vaccination Day 0 plan participate investigational drug trial next 26 week Definite plan travel dengue endemic area Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Dengue Vaccine</keyword>
	<keyword>Dengue Virus</keyword>
	<keyword>Dengue Hemorrhagic Fever</keyword>
	<keyword>Dengue Shock Syndrome</keyword>
</DOC>